The Most Potent Novel Psychedelics Ever Created | Bright Minds $DRUG
Bright Minds Biosciences Inc (NASDAQ: DRUG, CNSX: DRUG) designs and develops novel treatments to retain therapeutic aspects of psychedelics while minimizing the side effects. The company’s next-generation serotonin-based therapies can be applied to various illnesses such as neuropsychiatric disorders, epilepsy, and pain.
“Today, I would say we have the largest and most advanced psychedelic drug discovery program in the history of the world. That’s over 25 chemists working around the clock developing completely novel psychedelics. Some of the properties we have seen in these compounds are exceptional. These are outside of ergotamines which are drugs like LSD – these are the most psychedelics that have ever been created. They are not only potent but very targeted, meaning they do what we want them to do and do not act on other receptors that could lead to side effects that we don’t want to occur. Targeted therapies and very potent therapies, and we are likely to have best-in-class drugs in psychedelic medicine.” – Bright Minds CEO Ian Mcdonald
Bright Minds listed on NASDAQ last month, proving the legitimacy of its advanced drug discovery program. The company’s team of scientists has synthesized hundreds of de novo patentable psychedelic-based compounds and plans to announce its lead 5-HT2A molecule in the first quarter of 2022.
The company’s current lead program, BMB-101, advanced to IND-enabling toxicology studies and aims to commence human trials in the first half of 2022.
Watch the full interview to learn about the new psychedelic compounds Bright Minds is most excited about and the most potent drug the company has created.
Transcript
00:00 – Bright Minds BioSciences CEO Ian Mcdonald
00:45 – Bright Minds H2 2021 review
02:10 – FDA vs DEA
03:52 – Bright Mind novel drugs
08:27 – How soon until drugs are available
10:02 – Most exciting psychedelic compounds developed
Related Articles
Disclosure
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.
